AVXL Jan 2025 5.000 call
| Previous close | 0.8500 |
| Open | 0.6500 |
| Bid | 0.7000 |
| Ask | 0.8500 |
| Strike | 5.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.6500 - 0.7100 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.56k |
GlobeNewswireAnavex Life Sciences Announces Expansion of Leadership Team
Strengthening Operational Efficiency and Execution towards Sustainable Accessibility for Diverse Populations within Global Healthcare SystemsNEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schiz
Simply Wall St.Anavex Life Sciences (NASDAQ:AVXL) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
ZacksAnavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock?
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
